Evidence map›Paper›PMID 20015987›Full record

ArticleJournal of virology2010

Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Catherine A Blish, D Noah Sather, George Sellhorn, Leonidas Stamatatos, Yide Sun, Indresh Srivastava, Susan W Barnett, Brad Cleveland, Julie Overbaugh, Shiu-lok Hu

Abstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Catherine A BlishDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. cblish@fhcrc.org
D Noah Sather
George Sellhorn
Leonidas Stamatatos
Yide Sun
Indresh Srivastava
Susan W Barnett
Brad Cleveland
Julie Overbaugh
Shiu-lok Hu
Center for Infectious Disease Research · USFred Hutch Cancer Center · USUniversity of Washington · US

Funding

Combined Approach to Broadly Protective AIDS VaccinesP01AI054564 · NIAID · UNIVERSITY OF WASHINGTON · PI HU, SHIU-LOK · 2003 to 2007
$15.1M
Characterization of HIV-1 Antibody Responses in Chronically Infected WomenR01HD058304 · NICHD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2007 to 2011
$2.3M
Defining Immune Deficits in HIV-1 Infected WomenK08AI068424 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLISH, CATHERINE A · 2006 to 2010
$597k
NIAID NIH HHS K08 AI068424NIAID NIH HHS P01 AI054564NICHD NIH HHS HD058304NICHD NIH HHS R01 HD058304
6 · The paper itself

Abstract

Development of broadly cross-reactive neutralizing antibodies (NAbs) remains a major goal of HIV-1 vaccine development, but most candidate envelope immunogens have had limited ability to cross-neutralize heterologous strains. To evaluate the immunogenicity of subtype A variants of HIV-1, rabbits were immunized with pairs of closely related subtype A envelopes from the same individual. In each immunogen pair, one variant was readily neutralized by a variety of monoclonal antibodies and plasma antibodies, while the other was neutralization resistant, suggesting differences in the exposures of key epitopes. The breadth of the antibody response was evaluated against subtype A, B, C, and D variants of HIV-1. The specificity of the immunogen-derived neutralizing antibody response was also compared to that of the infected individuals from whom these variants were cloned. None of the immunogens produced broad neutralizing antibodies in immunized animals, and most of the neutralizing antibodies were directed to the variable loops, particularly the V3 loop. No detectable antibodies to either of the potentially exposed conserved epitopes, the membrane proximal external region, or the CD4 binding site were found with immunized rabbits. In contrast, relatively little of the neutralizing activity within the plasma samples of the infected individuals was directed to linear epitopes within the variable loops. These data indicate that immunogens designed to expose conserved regions did not enhance generation of broadly neutralizing antibodies in comparison with the immunogens that failed to expose those regions using this immunization approach.

Indexed as

AIDS VaccinesAmino Acid SequenceAnimalsAntibodies, NeutralizingAntibodies, Viralenv Gene Products, Human Immunodeficiency VirusEpitopesHIV-1HumansMolecular Sequence DataNeutralization TestsRabbitsSequence AlignmentAIDS VaccinesAntibodies, NeutralizingAntibodies, Viralenv Gene Products, Human Immunodeficiency VirusEpitopesgp140 envelope protein, Human immunodeficiency virus 1

Identifiers

PMID20015987
PMCPMC2820908
OpenAlexW1967011492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.